Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The combination of platinum compounds and vinorelbine is often used as a first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), without activating EGFR mutations and ALK rearrangement.
|
26220844 |
2015 |
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The National Comprehensive Cancer Network (NCCN) guidelines for patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR, BRAF, ERBB2, and MET mutations; ALK, ROS1, and RET rearrangements; and MET amplification.
|
27151654 |
2016 |
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Only for the small proportion of patients with metastatic NSCLC and genomic-driven tumors with EGFR or anaplastic lymphoma kinase (ALK)-sensitizing mutations (5%-15%), and possibly <i>BRAF</i> mutations and <i>ROS</i> rearrangements, have initial treatment recommendations remained unchanged, with specific tyrosine kinase inhibitors as the preferred therapy.
|
30642913 |
2019 |
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
|
26045865 |
2015 |
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.
|
31346927 |
2019 |
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the KEYNOTE-024 trial, pembrolizumab demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) versus Standard-of-Care (SoC) platinum-based doublets for first-line treatment of PD-L1 -positive (≥50%) metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR mutations or ALK translocations.
|
30642550 |
2019 |
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the role of conventional radiotherapy (RT) and stereotactic body radiotherapy (SBRT) in patients with epidermal growth factor (EGFR)-mutant or anaplastic lymphoma kinase (ALK) rearrangement-positive metastatic non-small cell lung cancer (NSCLC).
|
29275314 |
2018 |
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with stage IV NSCLC treated with an ALK inhibitor at the University of Colorado Cancer Center from 2009 through November 2017 were identified retrospectively.
|
30599201 |
2019 |
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A high pretreatment PLR is independently associated with poor survival in stage IV NSCLC with MPE and in a subgroup of epidermal growth factor receptor and anaplastic lymphoma kinase wild-type NSCLC.
|
30886226 |
2019 |
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rapid progression of metastatic non-small cell lung cancer (NSCLC) after discontinuation of tyrosine kinase inhibitors or anaplastic lymphoma kinase (ALK) inhibitors has been described and is associated with a poor prognosis.
|
30476657 |
2019 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.
|
28597393 |
2017 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
|
26582431 |
2016 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer.
|
31583605 |
2019 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
|
29458286 |
2018 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the USA, alectinib is indicated for the treatment of adults with ALK-positive metastatic NSCLC.
|
30030733 |
2018 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.
|
29959809 |
2018 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The FDA has approved the ALK inhibitor brigatinib for patients with metastatic non-small cell lung cancer who cannot take crizotinib or whose disease worsened despite its use.
|
28536155 |
2017 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The US FDA granted approval for crizotinib as the first-line treatment for patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearranged metastatic non-small-cell lung cancer, on November 20, 2013.
|
25797684 |
2015 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a case of crizotinib effectiveness in a heavily pretreated patient with a metastatic NSCLC initially considered IHC-positive and FISH-negative for ALK rearrangement.
|
27393517 |
2016 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Product Insert from two ALK-positive mNSCLC trials.
|
27328934 |
2016 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
|
25170012 |
2014 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data argue against PDGFRB activation in association with ALK gene aberrations in metastatic NSCLC and thus seem to imply differential pathobiological roles of ALK alterations in lung cancer and lymphoma, possibly depending on different fusion partner genes.
|
24750504 |
2014 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.
|
31482479 |
2019 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
|
30786826 |
2019 |
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two small molecule inhibitors of ALK, crizotinib and ceritinib, have been recently approved for the treatment of metastatic non-small-cell lung cancer, with marked improvement of progression-free survival of patients.
|
26618223 |
2016 |